Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’

Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively’


Cramer’s Mad Dash on Walgreens Boots: The stock should be bought 'perhaps aggressively'

CNBC’s Jim Cramer on Wednesday praised the incoming CEO of Walgreens Boots Alliance, saying industry veteran Tim Wentworth is the right choice to lead the struggling pharmacy chain in its transition to offering more health-care services.

“This guy is the real deal. I just salute him and think he can take you to a higher price, and the stock should be bought — perhaps aggressively,” Cramer said on “Squawk on the Street.”

Wentworth, whose appointment was announced Thursday night, previously served as CEO of Express Scripts, a pharmacy benefits manager acquired by health insurer Cigna in 2018. He stayed on for a few years as an executive at Cigna.

If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free.

Wentworth’s first day at Walgreens is set for Oct. 23, less than two months after former chief executive Roz Brewer left her post. The company said it was seeking a new CEO who had “deep” experience in the health-care industry.

Shares of Walgreens rose more than 1% Wednesday, to $22.66. However, so far in 2023, the Dow Jones Industrial Average constituent is down nearly 40%.

“I like Wentworth, and there is now hope for a stock that I held no hope for,” Cramer said.

The CNBC Investing Club portfolio does not own Walgreens but does have some exposure to health-care services via Amazon, which bought a primary care company and has an online prescription drug store.

Here’s a full list of the stocks in Jim’s Charitable Trust, the portfolio used by the CNBC Investing Club.



Source

Jim Cramer has faith in Danaher’s turnaround as life sciences comes back to life
Health

Jim Cramer has faith in Danaher’s turnaround as life sciences comes back to life

Life sciences stocks are seeing a resurgence — and that’s good news for Danaher . Connecting the dots to better times ahead for the struggling portfolio name, Jim Cramer thinks the industry turnaround is best illustrated by looking at Agilent Technologies ‘ recovery from a post-Covid rut. Shares are up around 50% from their April […]

Read More
‘Advice was so good,’ says CEO who used ChatGPT to pitch new ideas to AI versions of business icons
Health

‘Advice was so good,’ says CEO who used ChatGPT to pitch new ideas to AI versions of business icons

Joanna Stober, Midi Health CEO and co-founder, has never had an opportunity to run her business plans past legendary venture capital investor John Doerr, chairman at Kleiner Perkins. But that didn’t stop her from tapping Doerr, in an AI version, for advice on growing her startup, a virtual clinic offering midlife health care for women. […]

Read More
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Health

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the […]

Read More